相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation
Evan T. Ogburn et al.
DRUG METABOLISM AND DISPOSITION (2010)
Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin
Matthijs van Luin et al.
AIDS (2009)
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients
Awewura Kwara et al.
AIDS (2009)
CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or*17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients
Awewura Kwara et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine
Anne-Sophie Belanger et al.
DRUG METABOLISM AND DISPOSITION (2009)
Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis
Yuan Ren et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
Julia di Iulio et al.
PHARMACOGENETICS AND GENOMICS (2009)
Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients
Alberto Matteelli et al.
CURRENT HIV RESEARCH (2007)
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV
Gerald Friedland et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring
Naser L. Rezk et al.
THERAPEUTIC DRUG MONITORING (2006)
Cytochrome P4502B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity
Katarzyna K. Loboz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all
P Brennan-Benson et al.
AIDS (2005)
The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
BA Ward et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
C Csajka et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
C Marzolini et al.
AIDS (2001)
分享论文
